pSivida breaks BrachySil into Chinese market
This article was originally published in Clinica
Australian bio-nanotech company pSivida has licensed its BrachySil technology to Beijing Med-Pharm for marketing and distribution in the Chinese market. Under the terms of the agreement, pSivida will pay its newly-appointed distributor upfront and milestone payments totalling more than $2m for clinical development of the product and securing regulatory approval, as well as royalties of up to 30% on future sales. The Perth-based company will retain the manufacturing rights to BrachySil.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.